8004 ORAL Safety and Efficacy Outcomes in Heavily and Non-heavily Pretreated Patients With Recurrent Ovarian Cancer (ROC) After Single-agent Trabectedin Treatment – Pooled Analysis of Phase II Trials | Publicación